Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
Titel:
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
Auteur:
Campone, M. Bondarenko, I. Brincat, S. Hotko, Y. Munster, P.N. Chmielowska, E. Fumoleau, P. Ward, R. Bardy-Bouxin, N. Leip, E. Turnbull, K. Zacharchuk, C. Epstein, R.J.